Aggressive Breast Cancer Treatments Greenville NC

The drug tamoxifen is a tried-and-true way to lower the chances of developing the most common type of recurrence among breast cancer survivors, but new research suggests it raises the risk of getting a more aggressive cancer in the healthy breast by more than four times.

Ulf Lennart Karlsson, MD
(800) 782-8581
Greenville, NC
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Male
Education
Medical School: Karolinska Inst, Med Fak, Stockholm, Sweden
Graduation Year: 1968

Data Provided by:
Radhika Shah, MD
(252) 744-2560
Hem Onc Brody 3E 127 600 Moye Blvd
Greenville, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Howard David Homesley, MD
(252) 744-3587
Leo Jenkins Cancer Ctr
Greenville, NC
Specialties
Oncology (Cancer), Gynecological Oncology
Gender
Male
Education
Medical School: Univ Of Nc At Chapel Hill Sch Of Med, Chapel Hill Nc 27599
Graduation Year: 1967

Data Provided by:
James Ronald W Humbert, MD
(252) 816-4676
288 W Teaching Annex
Greenville, NC
Specialties
Oncology (Cancer), Pediatrics
Gender
Male
Education
Medical School: Centre Med Univ, Fac De Med, Geneve, Switzerland (Univ De Geneve)
Graduation Year: 1964

Data Provided by:
Cynthia A Lynch
(252) 744-1888
600 Moye Blvd
Greenville, NC
Specialty
Internal Medicine, Hematology / Oncology

Data Provided by:
Susan Gustke, MD
(252) 744-1000
202 W Berkshire Rd
Greenville, NC
Specialties
Internal Medicine, Hematology-Oncology
Gender
Female
Education
Medical School: Wv Univ Sch Of Med, Morgantown Wv 26506
Graduation Year: 1964
Hospital
Hospital: Pitt County Memorial Hospital, Greenville, Nc
Group Practice: Ecu Physicians Brody School Of Medicine

Data Provided by:
Gary Richard Jones, MD
(503) 494-1543
3282 Charles Blvd
Greenville, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Or Hlth Sci Univ Sch Of Med, Portland Or 97201
Graduation Year: 1980

Data Provided by:
Spencer O Raa, MR
(919) 551-2554
3E-106 Brody Bldg
Greenville, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Lillian P Burke, MD
(252) 744-2560
3E 127 Brody Med Sci Bldg
Greenville, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Pamela A Leper, MS
(252) 758-6788
Moye Blvd 3 E 127 Brody Science Bldg
Greenville, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Data Provided by:

Aggressive Breast Cancer Treatments

Provided By:

TUESDAY, Aug. 25 (HealthDay News) -- The drug tamoxifen is a tried-and-true way to lower the chances of developing the most common type of recurrence among breast cancer survivors, but new research suggests it raises the risk of getting a more aggressive cancer in the healthy breast by more than four times.

However, the finding is no reason to ditch the anti-cancer drug, as even the lead researcher emphasized.

"All treatments have risks and benefits," said study author Dr. Christopher Li, an associate member of the Fred Hutchinson Cancer Research Center in Seattle. "We know that the benefits of tamoxifen treatment clearly outweigh the risks. This study adds another risk, but doesn't change the overall balance. If you consider the full balance, for most women the benefits are going to far outweigh the risks."

Li and his colleagues evaluated tamoxifen use among 1,103 breast cancer survivors from the Seattle and Puget Sound area. The women were diagnosed initially with ER-positive breast cancer, the more common and less aggressive form, between the ages of 40 and 70.

Of those women, 369 developed a second breast cancer. Nearly all of those who took the hormonal therapy after surgery or other treatment used tamoxifen for five or more years. The researchers compared those who took tamoxifen with those who did not and found the drug, which blocks estrogen (which helps tumors grow) reduced ER-positive second breast cancers but boosted the risk of ER-negative tumors, which are less common but more aggressive.

"When we looked at the different types of second cancers, tamoxifen only lowered the risk of the more common and less aggressive type of cancer, ER-positive," Li said. "It lowered that by about 60 percent. But it increases the risk of developing ER-negative, the more aggressive cancer, by fourfold."

The study is published online Aug. 25 in the journal Cancer Research.

Exactly why the tamoxifen boosts the risk of ER-negative second cancers is not known, but Li said it could be that prolonged tamoxifen use provides "a competitive advantage for the growth of ER-negative breast cancer cells."

Other experts agreed that the study is no reason to give up on tamoxifen. "The thing we have to remember is tamoxifen saves lives," said Dr. Victor Vogel, national vice president of research at the American Cancer Society.

"Even though the risk of ER-negative goes up, only with five years or more, the risk of ER-positive [second breast cancer] goes down," he said. "We shouldn't lose sight of that."

"I worry people are going to panic if they are taking this drug," said Dr. Minetta Liu, director of translational breast cancer research at the Georgetown University Medical Center, in Washington, D.C. But they should not, she said, because "it has helped a huge number of women."

More information

To learn more about tamoxifen, visit the National Cancer Institute.

Author: By Kathleen Doheny
HealthDay Reporter

SOURCES: Victor Vogel, M.D., national vice president, research, American Cancer Society, Atlanta; Christopher Li, M.D., Ph.D., associate member, Fred Hutchinson Cancer Research Center, Seattle; Minetta Liu, M.D., director, translational breast cancer research, Georgetown University Medical Center, Washington, D.C.; August 25, 2009, Cancer Research

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com